Cargando…

Oral administration of Lactobacillus brevis 23017 combined with ellagic acid attenuates intestinal inflammatory injury caused by Eimeria infection by activating the Nrf2/HO-1 antioxidant pathway

The aim of this study was to investigate whether oral administration of Lactobacillus brevis 23017 (LB) alone and in combination with ellagic acid inhibits ChTLR15/ChNLRP3/ChIL-1β by activating the Nrf2/HO-1 pathway to attenuate intestinal inflammatory injury. Two animal experiments were performed....

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Xuelian, Pan, Xinghui, Jia, Zhipeng, Bai, Bingrong, Zhi, Wenjing, Chen, Hang, Ma, Chunli, Ma, Dexing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931975/
https://www.ncbi.nlm.nih.gov/pubmed/35303923
http://dx.doi.org/10.1186/s13567-022-01042-z
_version_ 1784671360091422720
author Yang, Xuelian
Pan, Xinghui
Jia, Zhipeng
Bai, Bingrong
Zhi, Wenjing
Chen, Hang
Ma, Chunli
Ma, Dexing
author_facet Yang, Xuelian
Pan, Xinghui
Jia, Zhipeng
Bai, Bingrong
Zhi, Wenjing
Chen, Hang
Ma, Chunli
Ma, Dexing
author_sort Yang, Xuelian
collection PubMed
description The aim of this study was to investigate whether oral administration of Lactobacillus brevis 23017 (LB) alone and in combination with ellagic acid inhibits ChTLR15/ChNLRP3/ChIL-1β by activating the Nrf2/HO-1 pathway to attenuate intestinal inflammatory injury. Two animal experiments were performed. In Experiment 1, chickens were allocated into 7 groups: PBS, and low, medium and high dosages of live and heat-killed LB, named L/LB(+), M/LB(+) and H/LB(+), and L/LB(−), M/LB(−) and H/LB(−), respectively. In Experiment 2, chickens were divided into 5 groups: PBS, challenge control, and low, medium and high dosages of ellagic acid combined with LB(+), named L/EA + L/LB(+), M/EA + M/LB(+) and H/EA + H/LB(+), respectively. Chickens were gavaged with LB with or without ellagic acid once a day. Then, the mRNA and protein levels of the components of the Nrf2/HO-1 pathway found in the caecal tissues were quantified. On Day 7 post-infection with E. tenella, the levels of the components of the ChTLR15/NLRP3/IL-1β pathway in the caeca were again quantified, and the anticoccidial effects were assessed. The results showed that the levels of the genes in the Nrf2/HO-1 pathway in the chickens in the LB(+) groups were higher than those in the LB(−) groups (p < 0.001); those in the H/LB(+) group were higher than those in the M/LB(+) and L/LB(+) groups (p < 0.001); and those in the H/EA + H/LB(+) group showed the highest expression levels compared with the other groups (p < 0.001). After challenge, the chickens in the H/LB(+) group displayed less inflammatory injury than those in the M/LB(+) and L/LB(+) groups (p < 0.05), and the chickens in the H/EA + H/LB(+) group showed stronger anti-inflammatory effects than the other groups (p < 0.05). Thus, these protective effects against infection were consistent with the above results. Overall, significant anti-inflammatory effects were observed in chickens orally gavaged with high dosages of live L. brevis 23017 and ellagic acid, which occurred by regulation of the ChTLR15/NLRP3/IL-1β pathway.
format Online
Article
Text
id pubmed-8931975
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-89319752022-03-23 Oral administration of Lactobacillus brevis 23017 combined with ellagic acid attenuates intestinal inflammatory injury caused by Eimeria infection by activating the Nrf2/HO-1 antioxidant pathway Yang, Xuelian Pan, Xinghui Jia, Zhipeng Bai, Bingrong Zhi, Wenjing Chen, Hang Ma, Chunli Ma, Dexing Vet Res Research Article The aim of this study was to investigate whether oral administration of Lactobacillus brevis 23017 (LB) alone and in combination with ellagic acid inhibits ChTLR15/ChNLRP3/ChIL-1β by activating the Nrf2/HO-1 pathway to attenuate intestinal inflammatory injury. Two animal experiments were performed. In Experiment 1, chickens were allocated into 7 groups: PBS, and low, medium and high dosages of live and heat-killed LB, named L/LB(+), M/LB(+) and H/LB(+), and L/LB(−), M/LB(−) and H/LB(−), respectively. In Experiment 2, chickens were divided into 5 groups: PBS, challenge control, and low, medium and high dosages of ellagic acid combined with LB(+), named L/EA + L/LB(+), M/EA + M/LB(+) and H/EA + H/LB(+), respectively. Chickens were gavaged with LB with or without ellagic acid once a day. Then, the mRNA and protein levels of the components of the Nrf2/HO-1 pathway found in the caecal tissues were quantified. On Day 7 post-infection with E. tenella, the levels of the components of the ChTLR15/NLRP3/IL-1β pathway in the caeca were again quantified, and the anticoccidial effects were assessed. The results showed that the levels of the genes in the Nrf2/HO-1 pathway in the chickens in the LB(+) groups were higher than those in the LB(−) groups (p < 0.001); those in the H/LB(+) group were higher than those in the M/LB(+) and L/LB(+) groups (p < 0.001); and those in the H/EA + H/LB(+) group showed the highest expression levels compared with the other groups (p < 0.001). After challenge, the chickens in the H/LB(+) group displayed less inflammatory injury than those in the M/LB(+) and L/LB(+) groups (p < 0.05), and the chickens in the H/EA + H/LB(+) group showed stronger anti-inflammatory effects than the other groups (p < 0.05). Thus, these protective effects against infection were consistent with the above results. Overall, significant anti-inflammatory effects were observed in chickens orally gavaged with high dosages of live L. brevis 23017 and ellagic acid, which occurred by regulation of the ChTLR15/NLRP3/IL-1β pathway. BioMed Central 2022-03-18 2022 /pmc/articles/PMC8931975/ /pubmed/35303923 http://dx.doi.org/10.1186/s13567-022-01042-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Yang, Xuelian
Pan, Xinghui
Jia, Zhipeng
Bai, Bingrong
Zhi, Wenjing
Chen, Hang
Ma, Chunli
Ma, Dexing
Oral administration of Lactobacillus brevis 23017 combined with ellagic acid attenuates intestinal inflammatory injury caused by Eimeria infection by activating the Nrf2/HO-1 antioxidant pathway
title Oral administration of Lactobacillus brevis 23017 combined with ellagic acid attenuates intestinal inflammatory injury caused by Eimeria infection by activating the Nrf2/HO-1 antioxidant pathway
title_full Oral administration of Lactobacillus brevis 23017 combined with ellagic acid attenuates intestinal inflammatory injury caused by Eimeria infection by activating the Nrf2/HO-1 antioxidant pathway
title_fullStr Oral administration of Lactobacillus brevis 23017 combined with ellagic acid attenuates intestinal inflammatory injury caused by Eimeria infection by activating the Nrf2/HO-1 antioxidant pathway
title_full_unstemmed Oral administration of Lactobacillus brevis 23017 combined with ellagic acid attenuates intestinal inflammatory injury caused by Eimeria infection by activating the Nrf2/HO-1 antioxidant pathway
title_short Oral administration of Lactobacillus brevis 23017 combined with ellagic acid attenuates intestinal inflammatory injury caused by Eimeria infection by activating the Nrf2/HO-1 antioxidant pathway
title_sort oral administration of lactobacillus brevis 23017 combined with ellagic acid attenuates intestinal inflammatory injury caused by eimeria infection by activating the nrf2/ho-1 antioxidant pathway
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931975/
https://www.ncbi.nlm.nih.gov/pubmed/35303923
http://dx.doi.org/10.1186/s13567-022-01042-z
work_keys_str_mv AT yangxuelian oraladministrationoflactobacillusbrevis23017combinedwithellagicacidattenuatesintestinalinflammatoryinjurycausedbyeimeriainfectionbyactivatingthenrf2ho1antioxidantpathway
AT panxinghui oraladministrationoflactobacillusbrevis23017combinedwithellagicacidattenuatesintestinalinflammatoryinjurycausedbyeimeriainfectionbyactivatingthenrf2ho1antioxidantpathway
AT jiazhipeng oraladministrationoflactobacillusbrevis23017combinedwithellagicacidattenuatesintestinalinflammatoryinjurycausedbyeimeriainfectionbyactivatingthenrf2ho1antioxidantpathway
AT baibingrong oraladministrationoflactobacillusbrevis23017combinedwithellagicacidattenuatesintestinalinflammatoryinjurycausedbyeimeriainfectionbyactivatingthenrf2ho1antioxidantpathway
AT zhiwenjing oraladministrationoflactobacillusbrevis23017combinedwithellagicacidattenuatesintestinalinflammatoryinjurycausedbyeimeriainfectionbyactivatingthenrf2ho1antioxidantpathway
AT chenhang oraladministrationoflactobacillusbrevis23017combinedwithellagicacidattenuatesintestinalinflammatoryinjurycausedbyeimeriainfectionbyactivatingthenrf2ho1antioxidantpathway
AT machunli oraladministrationoflactobacillusbrevis23017combinedwithellagicacidattenuatesintestinalinflammatoryinjurycausedbyeimeriainfectionbyactivatingthenrf2ho1antioxidantpathway
AT madexing oraladministrationoflactobacillusbrevis23017combinedwithellagicacidattenuatesintestinalinflammatoryinjurycausedbyeimeriainfectionbyactivatingthenrf2ho1antioxidantpathway